

Recombinant Mouse ASGR2 Fc Chimera

Catalog Number: 10447-AS

DESCRIPTION					
Source	Chinese Hamster Ovary cell line, CHO-derived mouse ASGR2 protein				
	MDP	Mouse IgG _{2A} (Glu98-Lys330)	IEGR	Mouse ASGR2 (Ser79-His301) Accession # P24721.1	
	N-terminus			C-terminus	
N-terminal Sequence Analysis	Met				
Structure / Form	Disulfide-linked homodimer				
Predicted Molecular Mass	53 kDa				

SPECIFICATIONS			
SDS-PAGE	62-81 kDa, under reducing conditions		
Activity	Measured by its binding ability in a functional ELISA. Immobilized Recombinant Mouse ASGR2 Fc Chimera (Catalog # 10447-AS) binds Human plasma von Willebrand Factor with an ED ₅₀ of 0.05-0.6 µg/mL.		
Endotoxin Level	<1.0 EU per 1 μ g of the protein by the LAL method.		
Purity	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.		
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS. See Certificate of Analysis for details.		

PREPARATION AND STORAGE				
Reconstitution	Reconstitute at 500 μg/mL in PBS.			
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.			
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles.			
	 12 months from date of receipt, -20 to -70 °C as supplied. 			
	 1 month. 2 to 8 °C under sterile conditions after reconstitution. 			

- 3 months, -20 to -70 °C under sterile conditions after reconstitution.



٠

DATA

Immobilized Recombinant Mouse ASGR2 Fc Chimera (Catalog # 10447-AS) binds human plasma von Willebrand Factor with an ED₅₀ of 0.05-0.6 µg/mL.

SDS-PAGE kDa NF 190 92 66 55 -Ξ 43 -36 29 21 18 -12 .

 $2\,\mu\text{g}/\text{lane}$ of Recombinant Mouse ASGR2 Fc Chimera (Catalog # 10447-AS) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 62-81 kDa and 120-160 kDa, respectively.

Rev. 5/12/2020 Page 1 of 2



Global bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL +1 612 379 2956 USA TEL 800 343 7475 Canada TEL 855 668 8722 China TEL +86 (21) 52380373 Europe | Middle East | Africa TEL +44 (0)1235 529449



Recombinant Mouse ASGR2 Fc Chimera

Catalog Number: 10447-AS

BACKGROUND

Asialoglycoprotein receptor 2 (ASGR2), also known as hepatic lectin 2 (HL-2), is an approximately 38 kDa member of the C-type lectin receptor family (1). ASGR2 is a single-pass type II transmembrane protein that plays a role in the endocytosis of desialylated glycoproteins, hepatic thrombopoietin production, and gastrointestinal malignancies (2, 3). ASGR2 is closely related to ASGR1 which is about 2 kDa smaller and is encoded by distinct but closely linked genes. Variations in ASGR2 structure due to alternative splicing have been reported (4-6). Mature ASGR2 consists of a cytoplasmic domain, transmembrane segment and an extracellular domain (ECD). Within the ECD, mouse ASGR2 shares 67% and 83% as sequence identity with human and rat ASGR2, respectively. Both ASGR2 and ASGR1 compose the asialoglycoprotein receptor (ASGPR) which mediates removal of potentially hazardous glycoconjugates from blood in health and disease (7). ASGPR, also known as the Ashwell receptor, can modulate von Willebrand factor (vWF) and platelet homeostasis in part via clearance of platelets that are first desialylated during sepsis asepsis, ASGR2 colocalization with plasma vWF was increased in ASGR1 deficient mice (8). In addition, ASGR2 expression was shown to be associated with malignant phenotypes in gastric cancer and may represent a specific biomarker for recurrence of some gastric cancers (9).

References:

- 1. Ishibashi, S. et al. (1994) J. Biol. Chem. 269:27803.
- 2. Grozovsky, R. et al. (2015) Nat Med. 1:47.
- 3. Tanaka, H. et al. (2018) Mol. Cancer Res. 16:1420.
- 4. Drickamer, K. *et al.* (1984) J. Biol. Chem. **259**:770.
- 5. Halberg, D.F. et al. (1987) J. Biol. Chem. 262:9828.
- 6. Paietta, E. et al. (1992) J. Biol. Chem. 267:11078.
- 7. Harris R.L. et al. (2012) Mol Biol Int. 2012:283974.
- 8. Grewal, P. et al. (2008) Nature Medicine. 14:6.
- 9. Tanaka H. et al. (2018) Mol Cancer Res. 16:1420.

Rev. 5/12/2020 Page 2 of 2



Global bio-techne.com info@bio-techne.com techsupport@bio-techne.com TEL +1 612 379 2956 USA TEL 800 343 7475 Canada TEL 855 668 8722 China TEL +86 (21) 52380373 Europe | Middle East | Africa TEL +44 (0)1235 529449